Risk of Developing a Second Primary Cancer in Male Breast Cancer Survivors: A Systematic Review and Meta-Analysis
View / Open Files
Authors
Hassan, Hend
Sofianopoulou, Eleni
Eccles, Diana M
Turnbull, Clare
Tischkowitz, Marc
Pharoah, Paul
Antoniou, Antonis C
Journal Title
British Journal of Cancer
ISSN
0007-0920
Publisher
Springer Nature [academic journals on nature.com]
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Allen, I., Hassan, H., Sofianopoulou, E., Eccles, D. M., Turnbull, C., Tischkowitz, M., Pharoah, P., & et al. Risk of Developing a Second Primary Cancer in Male Breast Cancer Survivors: A Systematic Review and Meta-Analysis. British Journal of Cancer https://doi.org/10.17863/CAM.87045
Abstract
Abstract
Background:
With increasing survival after cancer diagnosis, second primary cancers (SPCs) are becoming more prevalent. We investigated the incidence and site of non-breast SPC risks following male breast cancer (BC).
Methods:
PubMed, Embase and Web of Science were systematically searched for studies reporting standardized incidence ratios (SIRs) for SPCs published by March 2022. Meta-analyses used the generic inverse-variance method, assuming a random-effects model. We evaluated SIRs for overall SPCs, site-specific risks, by age at BC onset, time since BC onset and geographic region. We assessed study quality using routine techniques.
Results:
Eight population-based retrospective cohort studies were identified. SIRs ranged from 1.05 to 2.17. The summary SIR estimate was 1.27 (95%CI: 1.03-1.56, I2: 86%) and there were increased colorectal (SIR: 1.29, 95%CI: 1.03-1.61), pancreatic (SIR: 1.64, 95%CI: 1.05-2.55) and thyroid (SIR: 5.58, 95%CI: 1.04-30.05) SPC risks. When an outlying study was excluded, the summary SIR for men diagnosed with BC before age 50 was 1.50 (95%CI: 1.21-1.85), significantly higher than men diagnosed at older ages (SIR: 1.14, 95%CI: 0.98-1.33).
Conclusions:
Male BC survivors are at elevated risks of developing second primary colorectal, pancreatic, and thyroid cancers. The estimates may assist their clinical management and guide decisions on genetic testing.
Sponsorship
CRUK Catalyst Award CanGene-CanVar (C61296/A27223).
Funder references
Cancer Research UK (via Institute of Cancer Research (ICR)) (DGECATAAL)
Embargo Lift Date
2025-07-28
Identifiers
This record's DOI: https://doi.org/10.17863/CAM.87045
This record's URL: https://www.repository.cam.ac.uk/handle/1810/339627
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.